Abstract
Targeted drug delivery has attracted much attention in improving the curative effect of existing chemotherapy drugs, and many published studies have suggested the disulfide linkage for key unit in constructing a targeting conjugate. An appropriate disulfide bond, through which cytotoxic agents and drug carriers were linked together, would guarantee the conjugate stable during circulation in vivo and, readily cleavable to release the drug. The aim of this article is to review various design strategies based on disulfide linkage which have been used to assemble a tumor-targeting conjugate, with the goal of presenting a promising avenue in the field of targeted drug delivery.
Keywords: Disulfide, drug design, drug delivery, conjugate, tumor-targeting, antibody, reduction, drug release, endogenous glutathione, antitumor drug
Current Medicinal Chemistry
Title:Disulfide Linkage: A Potent Strategy in Tumor-Targeting Drug Discovery
Volume: 19 Issue: 18
Author(s): J. Wang, S. Li, T. Luo, C. Wang and J. Zhao
Affiliation:
Keywords: Disulfide, drug design, drug delivery, conjugate, tumor-targeting, antibody, reduction, drug release, endogenous glutathione, antitumor drug
Abstract: Targeted drug delivery has attracted much attention in improving the curative effect of existing chemotherapy drugs, and many published studies have suggested the disulfide linkage for key unit in constructing a targeting conjugate. An appropriate disulfide bond, through which cytotoxic agents and drug carriers were linked together, would guarantee the conjugate stable during circulation in vivo and, readily cleavable to release the drug. The aim of this article is to review various design strategies based on disulfide linkage which have been used to assemble a tumor-targeting conjugate, with the goal of presenting a promising avenue in the field of targeted drug delivery.
Export Options
About this article
Cite this article as:
Wang J., Li S., Luo T., Wang C. and Zhao J., Disulfide Linkage: A Potent Strategy in Tumor-Targeting Drug Discovery, Current Medicinal Chemistry 2012; 19 (18) . https://dx.doi.org/10.2174/092986712800672030
DOI https://dx.doi.org/10.2174/092986712800672030 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Physical and Structural Stability of the Monoclonal Antibody, Trastuzumab (Herceptin®), Intravenous Solutions
Current Pharmaceutical Biotechnology All in the Family: The TNF-TNFR Superfamily in the Pathogenesis and Treatment of Rheumatoid Arthritis and other Inflammatory Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Potential Application of Induced Pluripotent Stem Cells in Cell Replacement Therapy for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets PET/CT Based Dose Planning in Radiotherapy
Current Medical Imaging DephosSitePred: A High Accuracy Predictor for Protein Dephosphorylation Sites
Combinatorial Chemistry & High Throughput Screening Graphical Abstracts:
Current Cancer Drug Targets Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Current Drug Delivery Metabolites of Dietary Protein and Peptides by Intestinal Microbes and their Impacts on Gut
Current Protein & Peptide Science Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets Nanotechology-Based Strategies to Enhance the Efficacy of Photodynamic Therapy for Cancers
Current Drug Metabolism A Dual Role of Cyclin E in Cell Proliferation and Apotosis May Provide a Target for Cancer Therapy
Current Cancer Drug Targets Targeting Poly (ADP) Ribose Polymerase I (PARP-1) and PARP-1 Interacting Proteins for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Postmortem-Assessed Impairment of Neuronal Activity in Depression: The Dominant Impact of Suicide
CNS & Neurological Disorders - Drug Targets Phosphodiesterase 4 Inhibitors in Inflammatory Bowel Disease: A Comprehensive Review
Current Pharmaceutical Design The Other Side of the Opioid Story: Modulation of Cell Growth and Survival Signaling
Current Medicinal Chemistry Towards the Management of Inflammation: Recent Developments of mPGES-1 Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) In Vitro Anticancer Evaluation of Some Synthesized 2H-Quinolinone and Halogenated 2H-Quinolinone Derivatives as Therapeutic Agents
Anti-Cancer Agents in Medicinal Chemistry Role of Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) in Different Disease States: Recent Updates
Current Medicinal Chemistry Advances in Chemotherapy and Targeted Systemic Therapies for Urothelial Cancer
Current Drug Therapy Application of Monoclonal Antibodies as Cancer Therapy in Solid Tumors
Current Clinical Pharmacology